Clinical trials: Gastrointestinal Infection
Hepatitis C, Chronic
Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C
The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving…
- Trial name
- NCT00695019
- Testing
- interferon-alpha lozenges
- Where
- 9 sites in Taiwan
- Volunteers
- 169 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Chronic Hepatitis D Infection
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
- Trial name
- NCT07499544
- Testing
- Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug
- Where
- 7 sites in United States, China and 1 more
- Volunteers
- 160 people
- Sponsor
- Huahui Health
Shigellosis
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
This Phase 1 clinical trial is aimed to evaluate the safety and immunogenicity of 3 doses of 5 sequentially escalating dosages of a candidate vaccine against Shigella sonnei (1790GAHB vaccine) administered by intramuscular route…
- Trial name
- NCT02017899
- Testing
- S. sonnei 1790GAHB
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GSK Vaccines Institute For Global Health S.r.l.
Hepatitis C Virus
TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the steady-state pharmacokinetics of TMC278 or Tenofovir , and vice versa.
- Trial name
- NCT01205139
- Testing
- TMC435, TDF, TMC435 + TDF
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the treatment of hepatitis C virus genotype 1 in…
- Trial name
- NCT01016912
- Testing
- BMS-790052, Peginterferon alfa-2b, Ribavirin
- Where
- 6 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-H3733 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are…
- Trial name
- NCT05414981
- Testing
- ABI-H3733
- Where
- 9 sites in Bulgaria, Hong Kong and 4 more
- Volunteers
- 31 people
- Sponsor
- Assembly Biosciences
Hepatitis C Virus (HCV)
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in…
- Trial name
- NCT04214028
- Where
- 54 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with HBeAg negative chronic hepatitis B
- Trial name
- NCT00324961
- Testing
- adefovir dipivoxil tablets
- Where
- 18 sites in China
- Volunteers
- 533 people
- Sponsor
- GlaxoSmithKline
Hepatitis C
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir…
- Trial name
- NCT02441283
- Testing
- ABT-493, ABT-530
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 384 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
The objectives of this study are: 1. To evaluate the efficacy and safety of two different treatment regimens with BI 201335 (high dose given for 12 weeks or low dose given for 24 weeks both in combination with Pegylated…
- Trial name
- NCT01608737
- Testing
- PegIFN/RBV, BI 201335
- Sponsor
- Boehringer Ingelheim
Gastric Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
- Trial name
- NCT03050307
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 234 people
- Sponsor
- Takeda
Hepatitis C
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin (RBV) patients with chronic hepatitis C (HCV)…
- Trial name
- NCT01500772
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 6 people
- Sponsor
- Debiopharm International SA
Japanese Encephalitis, Hepatitis A
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi…
- Trial name
- NCT00735644
- Testing
- Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine
- Where
- 8 sites in Philippines, Thailand
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients
This trial is designed to evaluate the immunogenicity, reactogenicity and safety of an MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in haemodialysis patients with or without previous…
- Trial name
- NCT00699231
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Hepatitis C virus (HCV) infects approximately 170 million people worldwide. The current standard- of- care therapy of chronic HCV infection is a regimen of subcutaneously administered (pegylated)-interferon-α and ribavirin for 24…
- Trial name
- NCT00255177
- Testing
- VGX-410 (Mifepristone)
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VGX Pharmaceuticals, LLC
Hepatitis A
The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
The purpose of this follow-up study is to evaluate the five-year immune persistence of one injection of inactivated and attenuated alive hepatitis A vaccine in healthy children.
- Trial name
- NCT02002065
- Testing
- Inactivated HAV vaccine, Attenuated alive HAV vaccine
- Where
- China
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Liver Fibrosis, Cirrhosis
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
This prospective and multicenter study is to determine the diagnostic performance (accuracy, specificity and sensitivity) of transient elastography (FibroTouch) for liver fibrosis assessment in chronic hepatitis B (CHB) patients…
- Conditions
- Liver Fibrosis, Cirrhosis, Chronic Hepatitis B
- Trial name
- NCT02476695
- Testing
- FibroTouch Examination, FibroScan Examination, Ultrasonic B Examination
- Where
- 15 sites in China
- Volunteers
- 412 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Anthrax
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent…
- Trial name
- NCT07268612
- Testing
- CYFENDUS
- Volunteers
- 250 people
- Sponsor
- Emergent BioSolutions
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
This study will evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for 12 or 24 weeks in adults with chronic genotype 1 or genotype 4 hepatitis C virus (HCV)…
- Trial name
- NCT02251717
- Testing
- LDV/SOF
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 114 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.